In early 2017, injectable disease-modifying therapies (DMTs) captured the greatest share of multiple sclerosis (MS) patients recently initiated on their first DMT. With increasing first-line use of the oral DMTs, the approval of Genentech’s Ocrevus as a first-line option for patients with primary progressive MS (PPMS), and the availability of Mylan’s 40mg version of generic glatiramer acetate, both the new start MS patient profile and DMT treatment pattern are expected to have changed significantly. The below complimentary highlights are taken from the 2017 RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis US.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.

All company, brand or product names and logos in this document are trademarks of their respective holders.

Join Our Newsletter

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About Cookies page.OKREAD MORE